Abstract
Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.
| Original language | English |
|---|---|
| Pages (from-to) | 351-381 |
| Number of pages | 31 |
| Journal | Chemical Society reviews |
| Volume | 48 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 7 Jan 2019 |
Fingerprint
Cite this
}
Nanomedicine and macroscale materials in immuno-oncology. / Sun, Qingxue; Barz, Matthias; De Geest, Bruno G.; Diken, Mustafa; Hennink, Wim E.; Kiessling, Fabian; Lammers, Twan; Shi, Yang.
In: Chemical Society reviews, Vol. 48, No. 1, 07.01.2019, p. 351-381.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Nanomedicine and macroscale materials in immuno-oncology
AU - Sun, Qingxue
AU - Barz, Matthias
AU - De Geest, Bruno G.
AU - Diken, Mustafa
AU - Hennink, Wim E.
AU - Kiessling, Fabian
AU - Lammers, Twan
AU - Shi, Yang
PY - 2019/1/7
Y1 - 2019/1/7
N2 - Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.
AB - Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.
UR - http://www.scopus.com/inward/record.url?scp=85059232549&partnerID=8YFLogxK
U2 - 10.1039/c8cs00473k
DO - 10.1039/c8cs00473k
M3 - Review article
VL - 48
SP - 351
EP - 381
JO - Chemical Society reviews
JF - Chemical Society reviews
SN - 0306-0012
IS - 1
ER -